Maximizing the diversity of participants in a phase II clinical trial of optical technologies to detect cervical neoplasia

Gynecologic Oncology

Volumn 107, Issue 1 SUPPL., 2007, Pages

  Pham, Bryan ^a   Earle, Nan ^a   Rabel, Karen ^a   Follen, Michele ^a,b   Scheurer, Michael E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cervical neoplasia; Clinical trials; Optical technologies; Participant recruitment

Indexed keywords

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC PROCEDURE; ETHNICITY; FEMALE; GENETIC VARIABILITY; HEALTH CENTER; HEALTH STATUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PATIENT INFORMATION; PRIORITY JOURNAL; REFLECTOMETRY; TUMOR DIAGNOSIS; UTERINE CERVIX TUMOR;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; HUMANS; OPTICS; PATIENT SELECTION; SPECTROMETRY, FLUORESCENCE; UTERINE CERVICAL NEOPLASMS;

EID: 34848904481     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.07.063     Document Type: Article

References (15)

1. Sokolov K., Follen M., and Richards-Kortum R. Optical spectroscopy for detection of neoplasia. Curr Opin Chem Biol 6 5 (2002) 651-658
2. Littenberg B. Technology assessment in medicine. Acad Med 67 7 (1992) 424-428
3. Follen M., Crain S., MacAulay C., et al. Optical technologies for cervical neoplasia: update of an NCI program project grant. Clin Adv Hematol Oncol 3 1 (2005) 41-53
4. Gordis L. Epidemiology. 2nd edition (2000), W.B. Saunders Company, Philadelphia
5. Murthy V., Krumholz H., and Gross C. Participation in cancer clinical trials race-, sex-, and age-based disparities. Am Med Assoc 291 22 (2004) 2720-2726
6. Shuhatovich O., Sharman M., Mirabal Y., Earle N., Follen M., and Basen-Engquist K. Participant recruitment and motivation for participation in optical technology for cervical cancer screening research trials. Gynecol Oncol 99 3 Suppl 1 (2005) S226-S231
7. Lai G., Gary T., Tilburt J., et al. Effectiveness of strategies to recruit underrepresented populations into cancer clinical trials. Clin Trials 3 2 (2006) 133
8. Lindenstruth K., Curtis C., and Allen J. Recruitment of African American and white postmenopausal women into clinical trials: the beneficial effects of soy trial experience. Ethn Dis 16 4 (2006) 938-942
9. Bureau TUSC. http://factfinder.census.gov/servlet/QTTable?_bm=y&geo_id=04000US48 &-qr_name=DEC_2000_SF1_U_DP1&-ds_name=DEC_2000_SF1_U; 2000.
10. Canada S. http://www12.statcan.ca/english/census01/products/standard/prprofile/prp rofile.cfm?G=59. 2001.
11. Killien M.B.J., Champion V., Fernandez-Repollet E., Jackson R.D., Kagawa-Singer M., Kidd K., et al. Involving minority and underrepresented women in clinical trials: the National Centers of Excellence in Women's Health. J. Women's Health Gend.-Based Med. 9 10 (2000) 1061-1070
12. Brown D.R.F.M., Basen-Engquist K., and Tortolero-Luna G. Recruitment and retention of minority women in cancer screening, prevention, and treatment trials. Ann Epidemiol 10 Suppl. 8 (2000) S13-S21
13. Hartz M., and Beal J. Patients' attitudes and comfort levels regarding medical students' involvement in obstetrics-gynecology outpatient clinics. Acad Med 75 10 (2000) 1010-1014
14. Cox K., and Mcgarry J. Why patients don't take part in cancer clinical trials: an overview of the literature. Eur J Cancer Care 12 2 (2003) 114-122
15. S.M.U. Participation of minorities and women in clinical cancer research. Ann Epidemiol 10 8 Suppl (2000) S1-S2